{"changes":[{"companyHref":"/c/acurx-com","date":"2026-09-25","documentUrl":null,"domain":"acurx.com","fact":"latest round","name":"Acurx Pharmaceuticals, Inc.","new":{"amountUsd":4600000,"date":"2026-04-15","lead":null,"type":null},"old":{"amountUsd":4600000,"date":"2026-04-15","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-05-07","slug":"acurx-com","status":"attributed","url":"https://whoraisedwhat.com/c/acurx-com"}],"country":"US","description":"Acurx Pharmaceuticals is a clinical-stage biopharma developing a new class of antibiotics targeting bacteria listed as priority pathogens by the WHO, CDC, and FDA. It serves patients with serious resistant infections, with lead candidate ibezapolstat in trials. Its differentiator is a novel DNA polymerase IIIC inhibition mechanism.","domain":"acurx.com","employees":null,"founded":2017,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"pharmaceuticals","investors":[],"lat":40.586394,"lng":-74.093072,"location":"STATEN ISLAND, NY","name":"Acurx Pharmaceuticals, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":4600000,"currency":"USD","date":"2026-04-15","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"acurx-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"acurx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://acurx.com"},{"fact":"description","publisher":"acurx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://acurx.com"}],"stage":null,"techStack":[],"totalRaisedUsd":4600000,"updatedAt":"2026-05-07"}